^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    lomustine

    i
    Other names: CCNU
    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    3d
    GLIOSTELLA: A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Philogen S.p.A. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lomustine • Fibromun (onfekafusp alfa)
    9d
    A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme (clinicaltrials.gov)
    P2, N=252, Active, not recruiting, CNS Pharmaceuticals, Inc. | Trial completion date: Mar 2026 --> Jul 2026
    Trial completion date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    doxorubicin hydrochloride • lomustine • berubicin (RTA 744)
    11d
    Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma (clinicaltrials.gov)
    P3, N=200, Recruiting, Vastra Gotaland Region | Not yet recruiting --> Recruiting | Trial completion date: Dec 2031 --> Dec 2033 | Trial primary completion date: Dec 2028 --> Dec 2031
    Enrollment open • Trial completion date • Trial primary completion date
    |
    IDH wild-type
    |
    temozolomide • lomustine
    21d
    Actuate 1801: 9-ING-41 in Patients With Advanced Cancers (clinicaltrials.gov)
    P2, N=350, Active, not recruiting, Actuate Therapeutics Inc. | Trial completion date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jan 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    carboplatin • gemcitabine • albumin-bound paclitaxel • irinotecan • pegylated liposomal doxorubicin • lomustine • elraglusib (9-ING-41)
    21d
    GBM AGILE: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (clinicaltrials.gov)
    P2/3, N=2250, Recruiting, Global Coalition for Adaptive Research | N=1280 --> 2250
    Enrollment change
    |
    IDH wild-type
    |
    temozolomide • Stivarga (regorafenib) • lomustine • VT1021 • AZD1390 • Hepacid (pegargiminase) • paxalisib (GDC-0084) • dianhydrogalactitol (VAL-083) • Vyglxia (troriluzole) • tinostamustine (EDO-S101)
    22d
    Progression of primary mediastinal T-cell lymphoma to a multicentric form in a young dog. (PubMed, Can Vet J)
    Based on ex vivo drug sensitivity testing, lomustine was initiated as rescue chemotherapy, achieving a second complete remission...Key clinical message: This case highlights the fact that progression from primary mediastinal to multicentric lymphoma may be associated with a poor prognosis in dogs. Radiation therapy demonstrated potential efficacy and warrants further investigation as a treatment option for canine mediastinal lymphoma.
    Journal
    |
    CD4 (CD4 Molecule)
    |
    lomustine
    24d
    Mediastinal Lymphoma in 70 Dogs Treated With Lomustine or Anthracycline-Based Multi-Agent Chemotherapy. (PubMed, Vet Comp Oncol)
    This is the second study associating hypercalcaemia with improved PFS in dogs with non-indolent T-cell lymphoma. Results also suggest prognostic significance of specific CD4/CD8 expression patterns.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    lomustine
    26d
    MBMET_MEYER2017: An interventional, open-label, Phase II study, to evaluate safety and efficacy of standard and high-dose chemotherapy associated with craniospinal irradiation in patients with metastatic medulloblastoma and other embryonal tumours (2024-518964-11-01)
    P1/2, N=18, Active, not recruiting, Azienda Ospedaliera Universitaria Meyer IRCCS | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    carboplatin • cyclophosphamide • etoposide IV • vinorelbine tartrate • lomustine • thiotepa
    2ms
    A network-driven computational framework for identifying FDA-approved drug repurposing across heterogeneous brain cancers. (PubMed, Front Mol Biosci)
    As a result, three repurposed drugs were identified as priorities: (i) mefloquine (reference drug: vorasidenib citrate), (ii) clofibric acid (reference drug: carmustine), and armillarisin A (reference drug: lomustine). These results also suggest repurposing candidates for synergistic combinations across different brain tumors. The two applications developed in this work are freely accessible and in the public domain at https://assay.smallmoles.com/escorwin.
    FDA event • Journal
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • TERT (Telomerase Reverse Transcriptase) • KDR (Kinase insert domain receptor) • CDK1 (Cyclin-dependent kinase 1)
    |
    lomustine • carmustine • Voranigo (vorasidenib)
    2ms
    A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss (clinicaltrials.gov)
    P3, N=225, Recruiting, Children's Oncology Group | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Dec 2027 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • GLI2 (GLI Family Zinc Finger 2)
    |
    TP53 wild-type
    |
    cisplatin • cyclophosphamide • vincristine • lomustine
    2ms
    131I-TLX-101-003: A Phase III Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients with Recurrent Glioblastoma (2025-521785-10-00)
    P2/3, N=30, Not yet recruiting, Telix Pharmaceuticals (Innovations) Pty Limited
    New P2/3 trial
    |
    IDH wild-type
    |
    lomustine
    2ms
    NRG-BN011: Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma (clinicaltrials.gov)
    P3, N=265, Active, not recruiting, NRG Oncology | Suspended --> Active, not recruiting
    Enrollment closed
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    MGMT promoter methylation • IDH1 R132
    |
    temozolomide • lomustine